Technology area: Biotechnology & Pharmaceuticals
3 pending office actions • 2 art units • 3 examiners • 0 of 3 (0%) have an AI response strategy ready • 4 patents granted in the last 365 days
Voronoi Inc. has 3 pending office actions in Biotechnology & Pharmaceuticals. The matters involve 3 examiners across 2 art units, creating distinct examiner relationships with some overlap in technical assignment.
FERGUSON, JALISA HOLMES is the busiest examiner, with 1 pending matter. Counsel can coordinate issues that arise within the two art units while maintaining separate response strategies for each examiner.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §112 only | 1 (33%) |
| Multi-statute (no §101) | 2 (67%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| FERGUSON, JALISA HOLMES | 1 | 62.2% | +41.2% |
| HEITMEIER, KENDALL NICOLE | 1 | 65.1% | +41.1% |
| RODRIGUEZ-GARCIA, VALERIE | 1 | 68.9% | +31.7% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18705952 | QUINAZOLINE DERIVATIVE COMPOUND AND USE THEREOF | HEITMEIER, KENDALL NICOLE | — |
| 18692229 | HETEROARYL DERIVATIVE AND USE THEREOF | RODRIGUEZ-GARCIA, VALERIE | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18887279 | HETEROARYL DERIVATIVE COMPOUNDS, AND USES THEREOF | FERGUSON, JALISA HOLMES | — |
| 18705952 | QUINAZOLINE DERIVATIVE COMPOUND AND USE THEREOF | HEITMEIER, KENDALL NICOLE | — |
| 18692229 | HETEROARYL DERIVATIVE AND USE THEREOF | RODRIGUEZ-GARCIA, VALERIE | — |
| Art Unit | Apps |
|---|---|
| 1621 | 2 |
| 1626 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18887279 | HETEROARYL DERIVATIVE COMPOUNDS, AND USES THEREOF | FERGUSON, JALISA HOLMES | 1626 | §112 | Non-Final OA | — | Pending | Sep 17, 2024 |
| 18705952 | QUINAZOLINE DERIVATIVE COMPOUND AND USE THEREOF | HEITMEIER, KENDALL NICOLE | 1621 | §102§103§112 | Non-Final OA | — | Pending | Apr 29, 2024 |
| 18692229 | HETEROARYL DERIVATIVE AND USE THEREOF | RODRIGUEZ-GARCIA, VALERIE | 1621 | §103§112 | Non-Final OA | — | Pending | Mar 14, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialVoronoi Inc. has 3 pending office actions as of October 2026, spread across 2 art units and 3 examiners.
Jalisa Holmes Ferguson has the most, with 1 of Voronoi Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
